Boundless Bio, Inc. filings document a clinical-stage oncology issuer focused on ecDNA-directed cancer therapeutics, with formal disclosures on operating results, research programs, and material events. Recent 8-K reports furnish quarterly and annual financial results and business updates for BBI-940, KOMODO-1, and the discontinued POTENTIATE program involving BBI-355 and BBI-825.
Its proxy and current reports also cover board composition, director elections, auditor ratification, stockholder voting results, and facility-related obligations, including lease-termination arrangements. These filings frame the company’s clinical-development disclosures, public-company governance, capital allocation, and operating obligations.
Boundless Bio, Inc. granted Chief Scientific Officer Christian Hassig a stock option covering 230,000 shares of common stock on January 23, 2026. The option has an exercise price of $1.26 per share and was received at no cost on the grant date. It is held directly by the reporting person.
The vesting start date is January 1, 2026. The option vests in 48 substantially equal monthly installments, with 1/48 of the award vesting on February 1, 2026 and additional 1/48 portions vesting each month thereafter until fully vested.
Boundless Bio, Inc. Chief Medical Officer Robert Doebele reported receiving a stock option award on January 23, 2026. The option covers 230,000 shares of Boundless Bio common stock at an exercise price of $1.26 per share, held directly.
The vesting commencement date is January 1, 2026. The option vests in 48 substantially equal monthly installments, so 1/48th of the award vests on February 1, 2026 and then monthly thereafter until fully vested. Following this grant, Doebele beneficially owns 230,000 derivative securities in the form of stock options.
Boundless Bio, Inc. reported that its President and CEO, Zachary Hornby, received a grant of a stock option covering 600,000 shares of common stock. The option has an exercise price of $1.26 per share and was granted on January 23, 2026.
The option begins vesting from a commencement date of January 1, 2026, in 48 substantially equal monthly installments. As a result, 1/48th of the option vests on February 1, 2026, with additional monthly vesting thereafter until fully vested, and it is scheduled to expire on January 22, 2036.
Boundless Bio, Inc. reported that officer David A. Hinkle received a new stock option award. On January 23, 2026, he was granted an option to purchase 140,000 shares of common stock at an exercise price of $1.26 per share.
The option’s vesting start date is January 1, 2026. It vests in 48 substantially equal monthly installments, so 1/48 of the option vests on February 1, 2026 and then continues to vest monthly until fully vested on the fourth anniversary, assuming continued service.
Boundless Bio (Nasdaq: BOLD) filed its Q3 report and posted a net loss of $13.9 million. Operating expenses were $15.1 million, driven by research and development of $10.7 million and general and administrative of $4.5 million. Interest income was $1.3 million.
Liquidity remained solid with $117.6 million in cash, cash equivalents, and short‑term investments as of September 30, 2025. Management states this supports operations into the first half of 2028. The company has an at‑the‑market equity program of up to $14.5 million; no shares were sold under the program as of September 30, 2025.
Pipeline updates center on the POTENTIATE study: the BBI‑355 (CHK1 inhibitor) and BBI‑825 (RNR inhibitor) combination arm opened for enrollment in Q3 2025. Earlier monotherapy and third‑party combo arms of BBI‑355 were wound down in May 2025 as part of a portfolio prioritization and cost streamlining. Beyond the lead program, the company selected BBI‑940 (Kinesin degrader) as a development candidate and expects to submit an IND and start first‑in‑human testing in the first half of 2026. Shares outstanding were 22,385,611 as of October 31, 2025.
Boundless Bio (BOLD) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is being furnished and not filed under the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
RA Capital and related reporting persons reported they do not beneficially own any shares of Boundless Bio, Inc. The Schedule 13G/A for CUSIP 10170A100 lists RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah and shows aggregate beneficial ownership of 0.00 shares representing 0.0% of the class as of June 30, 2025. Each reporting person also disclaims status as a "group." The filing states the securities were not acquired to influence control of the issuer and incorporates a Joint Filing Agreement by reference.
Overview: Boundless Bio (Nasdaq: BOLD) is a clinical-stage precision oncology company focused on ecDNA-directed therapeutics (ecDTx). The company reported no revenue and an accumulated deficit of $232.9 million as of June 30, 2025.
Key financials (as of/for June 30, 2025): Cash and cash equivalents of $14.7 million, short-term investments of $112.5 million (total cash, cash equivalents and short-term investments of $127.1 million). Net loss was $31.4 million for the six months ended June 30, 2025 and $15.7 million for the quarter ended June 30, 2025. Operating cash used was $26.4 million for the six months ended June 30, 2025.
Operational and program updates: Company completed portfolio prioritization May 23, 2025, discontinued certain single-agent arms of BBI-355 and halted escalation of BBI-825 dosing, opened a BBI-355/BBI-825 combination arm in the POTENTIATE trial, selected kinesin degrader development candidate BBI-940 with an expected IND submission in H1 2026, and implemented a workforce reduction of approximately one-third. Management expects existing cash, cash equivalents, and short-term investments to fund operations into the first half of 2028.
Boundless Bio director Christine Brennan received a stock option grant on June 23, 2025. Key details of the transaction:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, and the filing was signed by Jessica Oien as attorney-in-fact for Christine Brennan. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.